Group 1 - The "Second Golden Unicorn Best Investment Advisor Selection" event is currently ongoing, with over 3,000 professional investment advisors participating in simulated trading competitions [1] - The event aims to provide a platform for investment advisors to showcase their capabilities, expand services, and enhance skills, while also facilitating communication between outstanding advisors and the public [1] Group 2 - The top ten ETFs by buy frequency as of September 30 include the Hong Kong Securities ETF, Gaming ETF, and Hong Kong Technology 50 ETF, among others [2] - The top ten ETFs by buy amount include the Hong Kong Securities ETF, Hong Kong Technology 50 ETF, and Hong Kong Innovative Drug ETF, indicating strong investor interest in these sectors [3] Group 3 - The data for the top buy stocks/ETFs is compiled from the most frequently purchased stocks/ETFs by all participating advisors, while the buy amount data reflects the top ten by total investment [4] - The competition includes a performance evaluation segment divided into stock simulation, on-site ETF simulation, and public fund simulation, with specific trading rules regarding holding proportions, maximum drawdown, and rebalancing frequency [4]

Group 1 - The core point of the article highlights the financing activities of Hong Kong New Drug (513780) on July 30, with a financing buy amount of 0.32 billion yuan, ranking 660th in the two markets [1] - Over the last three trading days from July 28 to July 30, Hong Kong New Drug received financing buys of 0.13 billion yuan, 0.39 billion yuan, and 0.32 billion yuan respectively [1] - On the same day, the company had no short selling activity, with both short selling and net selling at 0.00 shares [1]